Author(s): Ali Adel Dawood, Bassam Ismaeel Jasim


DOI: 10.5958/0975-4377.2021.00009.4   

Address: Ali Adel Dawood¹, Bassam Ismaeel Jasim²
¹Department of Anatomy, College of Medicine, University of Mosul, Mosul, Iraq
²Department of Internal Medicine, College of Medicine, University of Nineveh, Mosul, Iraq
*Corresponding Author

Published In:   Volume - 13,      Issue - 1,     Year - 2021

The CRISPR method is considered the biggest biotechnology breakthrough of the century because of its accuracy, effectiveness, and versatility, and it has opened up new possibilities for micro-genome editing and in vivo imaging. Overall, the technology of CRISPR / Cas9 has demonstrated unparalleled therapeutic promise to study and target diseases and to include innovative methods for drug development. To kill cancer cells, scientists are creating a groundbreaking CRISPER based genome editing treatment. A big step in the road to finding a cure for cancer is this recent growth. With other variants of CRISPR, scientists can change genes in more complex ways, such as inserting a new DNA segment or modifying single DNA letters.

Cite this article:
Ali Adel Dawood, Bassam Ismaeel Jasim. The CRISPR Genome Editing Process is an Effective Advancement of Short-Term Cancer Treatment. Res. J. Pharma. Dosage Forms and Tech.2021; 13(1):54-56. doi: 10.5958/0975-4377.2021.00009.4

1.    Martinez-Lage M, Puig-Serra P, Menendez P, Torres-Ruiz R, and Rodriguez-Perales S. CRISPR/Cas9 for Cancer Therapy: Hopes and Challenges. Biomed. 2018 Nov 12; 6(4):105. DOI: 10.3390/biomedicines6040105.
2.    Ravi T. Sivabalan. A study to evaluate the Quality of life in Head and Neck Cancer Patients admitted in Pravara Rural Hospital, Loni (Bk). Asian J. Nur. Edu. & Res. 2013; 3(1): Jan.-March; Page 21-24.
3.    Daniel R, Anna G, Ranit K, Srinivas R, Nuphar V, Ashley J, et al. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci Adv. 2020; 6 (47): eabc9450 DOI: 10.1126/sciadv.abc9450.
4.    Sampoornam W. Stress and Quality of Life among Breast Cancer Patients. Asian J. Nur. Edu. & Res. 2014; 4(3): July- Sept., 2014; Page 325-327.
5.    He S. The first human trial of CRISPR-based cell therapy clears safety concerns as new treatment for late-stage lung cancer. Sig Tran Tar Ther. 2020; 5:168.
6.    Ashmore-Harris C, and Fruhwirth O. The clinical potential of gene editing as a tool to engineer cell-based therapeutics. Clin Transl Med. 2020; 9(15). DOI: org/10.1186/s40169-020-0268-z.
7.    Stadtmauer A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020; 367.
8.    Adlin J. Effect of Foot Reflexology on Pain among Cancer Patients in Oncology Ward, Sri Ramakrishna Hospital, Coimbatore. Asian J. Nur. Edu. Res. 2011; 1(4): Oct-Dec. Page 107-108.
9.    Xu L. et al. CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. N Engl J Med. 2019; 381, 1240–1247. DOI: 10.1056/NEJMoa1817426.
10.    Kelly P. CRISPR takes first steps in humans. Science. 2020; 367(6481): 995-997. DOI:10.1126/science.367.6481.995-j.
11.    Abudayyeh O. et al. RNA targeting with CRISPR-Cas13. Nature. 2017; 550, 280–284.
12.    Gaj T, Gersbach A, and Barbas F. 3rd ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013; 31:397–405.
13.    Jisa George T, Kiran Batra. Beliefs and Attitude of Women Regarding Cervical Cancer Prevention and Screening in a Rural Community of Kerala. Asian J. Nur. Edu. Res. 2016; 6(1): 7-10.
14.    Jasmine Kaur. An Exploratory Study to Assess the Quality of Life among Cancer Patients of District Bathinda, Punjab. Asian J. Nur. Edu. Res. 2015; 5(1): Jan.-March; Page 18-22.
15.    Hampton T. With First CRISPR Trials, Gene Editing Moves Toward the Clinic. Med New Presp. 2020; 323(16):1537-1539. DOI:10.1001/jama.2020.3438.
16.    Neeta, Harish Dureja. Reverse Phase High-Performance Liquid Chromatographic Estimation and In vitro Cytotoxicity of Boswellic Acids on A-375 Melanoma Cancer Cell lines. Asian J. Pharm. Ana. 2018; 8(1): 13-19.
17.    Hamilton J, and Doudna J. Knocking out barriers to engineered cell activity. Science. 2020; 367 (6481): 976-977. DOI: 10.1126/science.aba9844.
18.    Tian X, Gu T, Patel S. et al. CRISPR/Cas9 – An evolving biological tool kit for cancer biology and oncology. npj Precis. Onc. 2019; 3.8.
19.    Hu Z. et al. Disruption of HPV16-E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells. Biomed. Res Int. 2014, 612823.
20.    Dawood A, and Yousif W. The Main Reasons Why Cancer Is So Difficult To Treatment. AJAMS. 2020; 2(2): 20-22.
21.    Lin S, Staahl T, Alla K, and Doudna A. Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. Elife. 2014; 3, e04766.
22.    Chertow D. S. Next-generation diagnostics with CRISPR. Science. 2018; 360, 381–382.
23.    Dawood A, Altobje M. Inhibition of N-linked Glycosylation by Tunicamycin May Contribute to The Treatment of SARS-CoV-2. Microbiol Path. 2020; 149:104586. 2020.104586.

Recomonded Articles:

Author(s): Dilip M. Kumbhar, Kailas K. Mali, Remeth J. Dias, Vijay D. Havaldar, Vishwajeet S. Ghorpade, Nitin H. Salunkhe.

DOI: 10.5958/0975-4377.2016.00036.7         Access: Open Access Read More

Author(s): Swati S Talokar, Rohan R Vakhariya

DOI: 10.5958/0975-4377.2017.00001.5         Access: Open Access Read More

Author(s): Rutuja R. Shah, Abhijeet Jadhav, Rohan R. Vakhariya

DOI: 10.5958/0975-4377.2017.00027.1         Access: Open Access Read More

Author(s): Kiran R. Birajdar, Satish K. Mandlik

DOI: 10.5958/0975-4377.2017.00015.5         Access: Open Access Read More

Author(s): Susmitha. A, Narendra Babu. K, Imran Khan Pathan, Ishwarya. K

DOI:         Access: Open Access Read More

Author(s): Borkar Sudarshan, Shende Vikas, Chatap Viveknand, Sawant Vilas, R Suresh, Dama Ganesh

DOI:         Access: Open Access Read More

Author(s): P. Parveen, P. Usha, V. Vasu Naik, Sk. Shaheda Sultana, M. Gayatri Ramya

DOI:         Access: Open Access Read More

Author(s): P.Sivannarayana, A. Prameela Rani, V. Saikishore, Ch.VenuBabu, V. SriRekha

DOI:         Access: Open Access Read More

Author(s): Pradeep Sahu, Swati Chaturvedi, Ravindra Dhar Dubey, Shweta Paroha, Shilpi Chatterjee, Tanushree Chatterjee

DOI:         Access: Open Access Read More

Author(s): Anusha. V

DOI:         Access: Open Access Read More

Author(s): Anilkumar J Shinde, Harinath N More

DOI:         Access: Open Access Read More

Author(s): Trilochan Satapathy, Prasanna Kumar Panda

DOI:         Access: Open Access Read More

Author(s): D. Saha, D. Mridha, S. Kayal, S. Beura

DOI:         Access: Open Access Read More

Author(s): Venkatesh Gavini, M. Srinivasa Murthy, P. Kiran Kumar

DOI:         Access: Open Access Read More

Author(s): S.C. Shivhare, Dr. U.D. Shivhare, Dr. Preeti Srivastav, K.G. Malviya

DOI:         Access: Open Access Read More

Author(s): Vijaya Kumar V., Raghuram N., K. Hari Krishna, K. Rajyalakshmi, Y. Indira Muzib

DOI:         Access: Open Access Read More

Author(s): Mary Charlet R. , Anuradha R.

DOI:         Access: Open Access Read More

Author(s): S.C. Shivhare, K.G. Malviya, Vijay Jain, Guatam Negi

DOI:         Access: Open Access Read More

Research Journal of Pharmaceutical Dosage Forms and Technology (RJPDFT) is an international, peer-reviewed journal, devoted to pharmaceutical sciences. ...... Read more >>>

RNI: Not Available                     
DOI: 10.5958/0975-4377 

Recent Articles